PMID- 31279152
OWN - NLM
STAT- MEDLINE
DCOM- 20200304
LR  - 20231213
IS  - 1872-7913 (Electronic)
IS  - 0924-8579 (Linking)
VI  - 54
IP  - 5
DP  - 2019 Nov
TI  - Off-label use of ceftaroline fosamil: A systematic review.
PG  - 562-571
LID - S0924-8579(19)30178-5 [pii]
LID - 10.1016/j.ijantimicag.2019.06.025 [doi]
AB  - Ceftaroline fosamil is a fifth-generation cephalosporin with 
      anti-methicillin-resistant Staphylococcus aureus (MRSA) activity. It has been 
      approved by the EMA and FDA for the treatment of adults and children with 
      community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin 
      structure infections (ABSSSI). However, ceftaroline fosamil has a broad spectrum 
      of activity, and a good safety and tolerability profile, so is frequently used 
      off-label. The aim of this systematic review was to summarize the safety and 
      efficacy of off-label use of ceftaroline. The review was conducted according to 
      PRISMA guidelines. MEDLINE, EMBASE and CENTRAL databases (2010-2018) were 
      searched using as the main term ceftaroline fosamil and its synonyms in 
      combination with names of infectious diseases of interest. A total of 21 studies 
      with 1901 patients were included: the most common off-label indications for 
      ceftaroline use were bacteremia (n=595), endocarditis (n=171), osteoarticular 
      infections (n=368), hospital-acquired pneumonia (n=115) and meningitis (n=23). 
      The most common reasons for off-label use were persistent or recurrent infection 
      after standard treatment or non-susceptibility to vancomycin and daptomycin. 
      Clinical success was evaluated in 933 patients, and 724 (77%) of these reached 
      this positive outcome. Incidence of adverse events (AEs) was reported in 11 
      studies. In 83 (9%) cases there were AEs related to the use of ceftaroline; the 
      most common reported AEs were nausea, vomiting, diarrhea, rash and neutropenia. 
      The review results show that ceftaroline may be used in clinical settings other 
      than those currently approved; however, the use of ceftaroline in these contexts 
      deserves further investigation.
CI  - Copyright (c) 2019 Elsevier B.V. and International Society of Chemotherapy. All 
      rights reserved.
FAU - Pani, Arianna
AU  - Pani A
AD  - Clinical Pharmacology Unit, ASST Grande Ospedale Metropolitano Niguarda, Italy; 
      Department of Oncology and Onco-Hematology, Postgraduate School of Clinical 
      Pharmacology and Toxicology University of Milan Statale, Italy. Electronic 
      address: arianna.pani@unimi.it.
FAU - Colombo, Fabrizio
AU  - Colombo F
AD  - Internal Medicine Department, ASST Grande Ospedale Metropolitano Niguarda, Italy. 
      Electronic address: fabrizio.colombo@ospedaleniguarda.it.
FAU - Agnelli, Francesca
AU  - Agnelli F
AD  - Internal Medicine Department, ASST Grande Ospedale Metropolitano Niguarda, Italy. 
      Electronic address: francesca.agnelli@ospedaleniguarda.it.
FAU - Frantellizzi, Viviana
AU  - Frantellizzi V
AD  - Department of Radiological, Oncological and Anatomical Pathological Sciences, 
      University of Rome Sapienza, Italy. Electronic address: 
      viviana.frantellizzi@uniroma1.it.
FAU - Baratta, Francesco
AU  - Baratta F
AD  - Department of Internal Medicine and Medical Specialties, University of Rome 
      Sapienza, Italy. Electronic address: francesco.baratta@uniroma1.it.
FAU - Pastori, Daniele
AU  - Pastori D
AD  - Department of Internal Medicine and Medical Specialties, University of Rome 
      Sapienza, Italy. Electronic address: daniele.pastori@uniroma1.it.
FAU - Scaglione, Francesco
AU  - Scaglione F
AD  - Clinical Pharmacology Unit, ASST Grande Ospedale Metropolitano Niguarda, Italy; 
      Department of Oncology and Onco-Hematology, Postgraduate School of Clinical 
      Pharmacology and Toxicology University of Milan Statale, Italy. Electronic 
      address: francesco.scaglione@unimi.it.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20190703
PL  - Netherlands
TA  - Int J Antimicrob Agents
JT  - International journal of antimicrobial agents
JID - 9111860
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Cephalosporins)
SB  - IM
MH  - Anti-Bacterial Agents/*therapeutic use
MH  - Bacteremia/drug therapy/microbiology
MH  - Cephalosporins/*therapeutic use
MH  - Community-Acquired Infections/*drug therapy/microbiology
MH  - Cross Infection/*drug therapy
MH  - Endocarditis, Bacterial/drug therapy/microbiology
MH  - Healthcare-Associated Pneumonia/drug therapy/microbiology
MH  - Humans
MH  - Meningitis/drug therapy/microbiology
MH  - Off-Label Use/*statistics & numerical data
MH  - Ceftaroline
OTO - NOTNLM
OT  - Bacteremia
OT  - Ceftaroline fosamil
OT  - Endocarditis
OT  - MRSA
OT  - Meningitis
OT  - Off-label
EDAT- 2019/07/07 06:00
MHDA- 2020/03/05 06:00
CRDT- 2019/07/07 06:00
PHST- 2018/12/14 00:00 [received]
PHST- 2019/06/25 00:00 [revised]
PHST- 2019/06/28 00:00 [accepted]
PHST- 2019/07/07 06:00 [pubmed]
PHST- 2020/03/05 06:00 [medline]
PHST- 2019/07/07 06:00 [entrez]
AID - S0924-8579(19)30178-5 [pii]
AID - 10.1016/j.ijantimicag.2019.06.025 [doi]
PST - ppublish
SO  - Int J Antimicrob Agents. 2019 Nov;54(5):562-571. doi: 
      10.1016/j.ijantimicag.2019.06.025. Epub 2019 Jul 3.